Mankind Pharma Share Price Closed Higher at ₹2,347.60 on Block Deal News — What It Means for Investors

Mankind Pharma: what is happening in Thursday's session

Mankind Pharma (MANKIND) last traded at ₹2,347.60, +12.60 (+0.54%) against a previous close of ₹2,335.00, read from the NSE board at the close of the last trading session on Thursday, 15 October 2026. On the tape the move is inside the stock's usual daily range, so the tape is treating the story as information rather than as a reason to reprice.

The market is closed at the time of writing (Friday, 12:05 am IST); the levels below are the close of the Thursday, 15 October 2026 session.

The story in five lines

• Where it trades: Mankind Pharma is at ₹2,347.60, +12.60 (+0.54%) versus the previous close of ₹2,335.00.
• Why it is moving: a block-deal story — 2 business desks filed on the company in the last few hours.
• Today's band: ₹2,321.10 to ₹2,365.00, against an open of ₹2,325.60 — the stock is defending its opening print.
• Twelve-month context: 11.14% below the ₹2,642 high and 22.93% above the ₹1,910 low, so the stock sits in the middle part of its own range.
• Participation: turnover is running at 1.1x the twenty-day average, which is ordinary flow — the move lacks a volume endorsement so far.
• What to watch: who the counterparties were and whether the buyer is a long-only fund or a trading desk, because a lock-in changes how much of the supply actually returns to the market.

The block deal angle

The reason Mankind Pharma is on the desks in Thursday's session is a block deal story — run by 2 publishers, with the headlines linked below. Large negotiated trades change the shareholder register in one print, and the discount or premium at which the block clears is the cleanest read on what institutions think the stock is worth today.

Live price snapshot

What a block deal tells you that the screen price does not

A block or bulk deal is a negotiated trade executed in one print, usually between an institution reducing a position and one or several buyers taking it on. Because both sides agree a price before the trade hits the tape, the discount or premium to the prevailing market price is the single cleanest read available on what large money thinks Mankind Pharma is worth today.

The identity of the buyer matters more than the size. A long-only fund taking delivery implies the paper is off the market for quarters; an arbitrage or trading desk taking it implies the same stock returns as supply within weeks. Exchange bulk-deal disclosures name both sides after the close, which is why the day-after reaction is often more informative than the day-of one.

On the board, MANKIND is at ₹2,347.60 against a session range of ₹2,321.10 to ₹2,365.00. If the block cleared inside that range, the market has already absorbed it; a block struck well below the range low usually caps the stock until the buyer stops adding.

Reading today's session

Mankind Pharma has traded between ₹2,321.10 and ₹2,365.00 in this session against an open of ₹2,325.60 and a previous close of ₹2,335.00. That is a band of ₹43.90, or 1.87% of the current price — an ordinary day's spread, so the move is orderly rather than disorderly.

Holding above the open at ₹2,325.60 matters because it is the level intraday desks use as the session pivot: buyers who entered at the open are in profit, so there is no forced supply from that cohort.

In market-structure terms this is a continuation session, so the prior trend remains the base case until a level breaks.

The headlines behind this post

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Mankind Pharma to acquire 70% in Belgian biotech firm for €48 million — Business Standard
• Mankind Pharma to acquire 70% stake in Belgium’s ACTx for €48 million — The Hindu BusinessLine

How the stock has performed

What the returns table is saying

Over the last week Mankind Pharma has slipped -6.10% and over the month +2.96%. The two horizons pointing in opposite directions is the signature of a counter-trend move — the shorter reading is either an early turn or a pullback inside the bigger trend, and volume is what separates the two.

The twelve-month return of -4.01% is the context long-term holders judge the stock on. A moderate one-year move means the stock has broadly tracked its earnings path rather than being re-rated in either direction.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹1,910 to ₹2,642. The current level is 60% of the way through that band, 11.14% below the 52-week high and 22.93% above the 52-week low. A mid-range price means neither the bulls nor the bears own the trend yet; the twelve-month extremes are the levels that decide which way the range resolves.

Traded quantity of 6,45,492 shares is 1.07x the 20-day average of 6,02,946. Turnover close to the recent norm suggests an orderly session rather than a scramble, so the move reflects ordinary two-way flow.

What to watch next

For this block deal story specifically, watch who the counterparties were and whether the buyer is a long-only fund or a trading desk, because a lock-in changes how much of the supply actually returns to the market. On the chart, the ₹2,365.00 high and ₹2,321.10 low of the last session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of that low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 6,02,946 shares to be read as positioning rather than a squeeze.

So what should shareholders do with this?

For a trader, this is a low-information session: the move sits inside the stock's normal daily spread, so there is no edge in chasing it. Waiting for a close outside ₹2,321.10–₹2,365.00 is the cheaper way to be positioned.

For a long-term shareholder, supply-driven weakness is a different thing from deterioration. Nothing in this event changes what the company earns; it changes who owns it and at what price. The question worth asking is whether the post-event share count and the use of proceeds leave earnings per share better or worse than before.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

Where that leaves the stock

Mankind Pharma is being bought on a block-deal story, and at ₹2,347.60 the move is not yet backed by turnover above its own average, which is the version of a rally that tends to fade. The day's ₹2,321.10–₹2,365.00 band is the frame for the next session, and who the counterparties were and whether the buyer is a long-only fund or a trading desk is what resolves the story either way.

Where to track MANKIND next

Live price, charts and technicals stay on the Mankind Pharma stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Mankind Pharma share price in Thursday's session?

Mankind Pharma (MANKIND) last traded at ₹2,347.60, +12.60 (+0.54%) against the previous close of ₹2,335.00, read from the NSE board at the close of the last trading session on Thursday, 15 October 2026.

Why is Mankind Pharma in the news in Thursday's session?

2 business publishers ran headlines on the company in the last session — a block deal story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of MANKIND?

Over the last twelve months MANKIND has traded between a low of ₹1,910 and a high of ₹2,642, computed from the adjusted daily series.

Is MANKIND up or down in Thursday's session?

MANKIND gained +0.54% in the last session, trading between ₹2,321.10 and ₹2,365.00 against an open of ₹2,325.60.

Is the market open right now?

No. The market is closed at the time of writing (Friday, 12:05 am IST); the levels below are the close of the Thursday, 15 October 2026 session.

Key takeaways

• Last price: ₹2,347.60 (+0.54%) — higher at the time of writing
• Day range: ₹2,321.10 – ₹2,365.00
• 52-week high: ₹2,642

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Mankind Pharma share price
• Mankind Pharma quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Mankind Pharma stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”